Publication:
World Bank Pharmaceuticals

Simple item page
dc.contributor.authorReich, Michael R.
dc.contributor.authorGovindaraj, Ramesh
dc.contributor.authorCohen, Jillian C.
dc.date.accessioned2013-06-04T19:31:08Z
dc.date.available2013-06-04T19:31:08Z
dc.date.issued2000-09
dc.description.abstractPharmaceuticals have a major impact on health, on government and household spending, and on health systems. Despite the fundamental role of pharmaceuticals, there remains a profound gap between the benefit which pharmaceuticals have to offer and the reality that for millions of people -- particularly poor and disadvantaged people -- medicines are unavailable, unaffordable, unsafe or improperly used. This World Bank Pharmaceuticals Discussion Paper provides a pragmatic analysis of some of the causes for this gap and strategic directions to help close this gap. The strategic directions outlined in this Pharmaceuticals Discussion Paper complement and reinforce the objectives outlined in the WHO Medicines Strategy: 2000-2003 (World Health Organization, Geneva, 2000, WHO/EDM/2000.1). The WHO strategy describes specific objectives, expected outcomes, and progress indicators in the areas of drug policy, access to essential drugs, quality and safety, and rational use of medicines. Both the World Bank and the WHO initiatives rest on a fundamental commitment to work with governments, on governmental organizations, the private sector, professional bodies, and other key actors to help strengthen the pharmaceutical sector and its ability to contribute to improved health outcomes.. The current burden of disease falling on the two billion people living on less than one dollar per day undermines both individual well-being and collective economic development. Much of this burden of disease can be reduced by securing the availability, affordability, and rational use of essential drugs of assured quality. Yet this aim can not be achieved by governments alone, by individual multilateral organizations working alone, or by any other individual organization. It can only be achieved when committed governments and local organizations are supported by clear, consistency, and mutually compatible approaches by agencies such as the World Bank, WHO, UNICEF, others in the UN family, bilateral donors, and the broader development community. This discussion paper provides an important contribution to this process.en
dc.identifierhttp://documents.worldbank.org/curated/en/2000/09/3928594/world-bank-pharmaceuticals
dc.identifier.doi10.1596/13734
dc.identifier.urihttps://hdl.handle.net/10986/13734
dc.languageEnglish
dc.language.isoen_US
dc.publisherWorld Bank, Washington, DC
dc.relation.ispartofseriesHNP discussion paper series;
dc.rightsCC BY 3.0 IGO
dc.rights.holderWorld Bank
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/igo/
dc.subjectAPPRAISAL REPORTS
dc.subjectBIDDING
dc.subjectCAPACITY BUILDING
dc.subjectCASE STUDY
dc.subjectCONTRACEPTIVES
dc.subjectCORRUPTION
dc.subjectCOUNTERFEIT DRUGS
dc.subjectDECISION MAKING
dc.subjectDELIVERY SYSTEMS
dc.subjectDEVELOPED COUNTRIES
dc.subjectDEVELOPING COUNTRIES
dc.subjectDEVELOPING COUNTRY
dc.subjectDEVELOPMENT GOALS
dc.subjectDEVELOPMENT INDICATORS
dc.subjectDEVELOPMENT NETWORK
dc.subjectDEVELOPMENT PARTNERS
dc.subjectDEVELOPMENT STUDIES
dc.subjectDISTRIBUTION SYSTEMS
dc.subjectDRUG FINANCING
dc.subjectDRUG INDUSTRY
dc.subjectDRUG POLICY
dc.subjectDRUG SELECTION
dc.subjectECONOMIC GROWTH
dc.subjectECONOMICS
dc.subjectESSENTIAL DRUGS
dc.subjectFINANCIAL SUPPORT
dc.subjectFORMAL POLICY
dc.subjectHEALTH CARE
dc.subjectHEALTH CARE PROVISION
dc.subjectHEALTH EXPENDITURES
dc.subjectHEALTH NEEDS
dc.subjectHEALTH OUTCOMES
dc.subjectHEALTH POLICY
dc.subjectHEALTH SECTOR
dc.subjectHEALTH WORKERS
dc.subjectHEPATITIS B
dc.subjectHOUSEHOLD INCOME
dc.subjectHUMAN CAPITAL
dc.subjectHUMAN DEVELOPMENT
dc.subjectIMPORTED DRUGS
dc.subjectIMPROVED HEALTH
dc.subjectINCOME COUNTRIES
dc.subjectINDIVIDUAL COUNTRIES
dc.subjectINSTITUTIONAL ANALYSIS
dc.subjectINTERNATIONAL MARKET
dc.subjectINTERVENTION
dc.subjectLOW-INCOME COUNTRIES
dc.subjectMALARIA
dc.subjectMANAGEMENT
dc.subjectMANAGEMENT CAPACITY
dc.subjectMANAGERS
dc.subjectMARKET FAILURES
dc.subjectMARKET INCENTIVES
dc.subjectMEDICAL SUPPLIES
dc.subjectMEDICINE
dc.subjectMEDICINES
dc.subjectMOTIVATION
dc.subjectNATIONAL DRUG POLICIES
dc.subjectNATIONAL DRUG POLICY
dc.subjectNATIONAL ESSENTIAL DRUG LISTS
dc.subjectNATIONAL ESSENTIAL DRUGS LISTS
dc.subjectNATIONAL POLICIES
dc.subjectNDP
dc.subjectNON- GOVERNMENTAL ORGANIZATIONS
dc.subjectNUTRITION
dc.subjectPARTNER INSTITUTIONS
dc.subjectPARTNERSHIP
dc.subjectPATENTS
dc.subjectPATIENTS
dc.subjectPHARMACEUTICAL COMPANIES
dc.subjectPHARMACEUTICAL FINANCING
dc.subjectPHARMACEUTICAL INDUSTRY
dc.subjectPHARMACEUTICAL MANUFACTURERS
dc.subjectPHARMACEUTICAL MARKETING
dc.subjectPHARMACEUTICAL MARKETS
dc.subjectPHARMACEUTICAL POLICIES
dc.subjectPHARMACEUTICAL POLICY
dc.subjectPHARMACEUTICAL PRICING
dc.subjectPHARMACEUTICAL PROCUREMENT
dc.subjectPHARMACEUTICAL PRODUCTION
dc.subjectPHARMACEUTICAL PRODUCTS
dc.subjectPHARMACEUTICAL REFORM
dc.subjectPHARMACEUTICAL REGULATORY AGENCIES
dc.subjectPHARMACEUTICAL SECTOR
dc.subjectPHARMACEUTICAL SUPPLY
dc.subjectPHARMACEUTICAL SYSTEMS
dc.subjectPHARMACEUTICAL WAREHOUSING
dc.subjectPHARMACEUTICALS
dc.subjectPHARMACIES
dc.subjectPOLICY ANALYSIS
dc.subjectPOLICY DIALOGUE
dc.subjectPOLICY DOCUMENT
dc.subjectPOLICY FRAMEWORK
dc.subjectPOLICY IMPLICATIONS
dc.subjectPOLICY PROCESS
dc.subjectPRICE COMPARISONS
dc.subjectPRIMARY HEALTH CARE
dc.subjectPRIVATE SECTOR
dc.subjectPRIVATE SECTORS
dc.subjectPROJECT IMPLEMENTATION
dc.subjectPUBLIC AGENCIES
dc.subjectPUBLIC HEALTH
dc.subjectPUBLIC POLICIES
dc.subjectPUBLIC POLICY
dc.subjectPUBLIC SECTOR
dc.subjectPURCHASING
dc.subjectQUALITY ASSURANCE
dc.subjectQUALITY CONTROL
dc.subjectRATIONAL USE OF DRUGS
dc.subjectSAFETY
dc.subjectSCHOOLS
dc.subjectSOCIAL MARKETING
dc.subjectSTRUCTURAL ADJUSTMENT
dc.subjectTASK TEAM LEADERS
dc.subjectTECHNICAL ASSISTANCE
dc.subjectTHERAPIES
dc.subjectVACCINES
dc.subjectWIDESPREAD CORRUPTION
dc.subjectWORKERS PHARMACEUTICALS
dc.subjectBURDEN OF DISEASE
dc.subjectHEALTH CARE SYSTEMS
dc.subjectMULTILATERAL ORGANIZATIONS
dc.subjectHEALTH CARE
dc.subjectHEALTH CARE FINANCE
dc.subjectHEALTH CARE FINANCING
dc.subjectHEALTH SYSTEMS DEVELOPMENT & REFORM
dc.titleWorld Bank Pharmaceuticalsen
dspace.entity.typePublication
okr.date.doiregistration2025-05-05T12:32:28.452802Z
okr.doctypePublications & Research::Working Paper
okr.doctypePublications & Research
okr.docurlhttp://documents.worldbank.org/curated/en/2000/09/3928594/world-bank-pharmaceuticals
okr.globalpracticePoverty
okr.guid757701468764990351
okr.identifier.externaldocumentum000265513_20040603124203
okr.identifier.internaldocumentum3928594
okr.identifier.report28876
okr.language.supporteden
okr.pdfurlhttp://www-wds.worldbank.org/external/default/WDSContentServer/WDSP/IB/2004/06/03/000265513_20040603124203/Rendered/PDF/288760Govindar1Pharmacuetical1whole.pdfen
okr.topicHealth Monitoring and Evaluation
okr.topicPharmaceuticals and Pharmacoeconomics
okr.topicHealth Economics and Finance
okr.topicPharmaceuticals Industry
okr.topicPoverty Reduction::Poverty Assessment
okr.unitHealth, Nutrition & Popultn Team (HDNHE)
okr.volume1 of 1
relation.isAuthorOfPublicationa1e69d35-3306-5de0-937c-3b0f2a30022c
relation.isAuthorOfPublication.latestForDiscoverya1e69d35-3306-5de0-937c-3b0f2a30022c
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
288760Govindar1Pharmacuetical1whole.pdf
Size:
633.62 KB
Format:
Adobe Portable Document Format
Download
No Thumbnail Available
Name:
288760Govindar1Pharmacuetical1whole.txt
Size:
101.53 KB
Format:
Plain Text
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:
Download
Collections
Health, Nutrition and Population (HNP) Discussion Papers